NeuroRx and Relief Therapeutics have completed enrollment for their phase 2b/3 clinical trial for their treatment of respiratory failure in patients with severe cases of COVID-19. The trial, who’s top-line data is expected in one month, has expanded enrollment to 165 participants, and despite the rejection of their Emergency Use Authorization (EUA) of the drug by the U.S. Food and Drug Administration (FDA), the pharmaceutical companies remain committed to carrying out their clinical trials for approval. Since July of 2020, the drug has been used to treat over 300 patients suffering from COVID-19 respiratory failure.
Read more here.
More on: News Regulatory